XPORT-EC-042 / ENGOT-EN20 / GOG-3083
A promising subgroup finding from an earlier trial did not hold up: selinexor maintenance missed its main goal in TP53-normal endometrial cancer.
The primary PFS endpoint was not met (topline 30 July 2026). A trend favoured selinexor in the modified intent-to-treat population (median PFS 12.75 vs 7.43 months), consistent with the SIENDO exploratory subgroup that motivated the trial, but not statistically significant. Karyopharm cut its endometrial investment. A lesson in the limits of post-hoc biomarker subgroups.
- Median 12.8 vs 7.4 months with Selinexor compared with Placebo; about 5.3 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- The p-value (not significant) means the difference could plausibly be due to chance.
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: TP53-wild-type advanced or recurrent endometrial cancer after response to platinum: maintenance selinexor vs placebo. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (TP53); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Pages like this
not linked directly; found by shared links- ProductEprenetapopt
Shares TP53 and the tag failure.
- IdeaHER2 ADCs as standard for HER2-positive serous endometrial cancer
Shares TP53, Endometrial cancer.
- TrialPORTEC-3
Shares TP53, Endometrial cancer.
- TermEndometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP)
Shares TP53, Endometrial cancer.
- IdeaMolecular-class-directed adjuvant therapy in endometrial cancer
Shares TP53, Endometrial cancer.
- TermTP53-mutated (p53-abnormal)
Shares TP53, Endometrial cancer.